REMODEL — Semaglutide mechanism-of-action MRI and biopsy trial in type 2 diabetes with CKD (2026) — Trial Summary
REMODEL — Semaglutide mechanism-of-action MRI and biopsy trial in type 2 diabetes with CKD (2026): Randomized, placebo-controlled, 2:1 mechanistic trial of subcutaneous semaglutide 1.0 mg once weekly versus placebo for 52 weeks in adults with type 2 diabetes and chronic kidney disease (eligibility a
References
- Tuttle KR, Bjornstad P, Smith C, et al. Effects of semaglutide on kidney disease in type 2 diabetes: a randomized placebo-controlled trial. Nat Med. Published online October 1, 2026. doi:10.1038/s41591-026-04674-2